NovoCure Limited (038.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
As of 09:24AM CEST. Market open.
| Previous close | 14.62 |
| Open | 15.41 |
| Bid | 15.01 x 50000 |
| Ask | 15.24 x 40000 |
| Day's range | 14.82 - 15.41 |
| 52-week range | 10.08 - 78.30 |
| Volume | |
| Avg. volume | 27 |
| Market cap | 1.643B |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Insider Monkey
NovoCure Limited (NASDAQ:NVCR) Q1 2024 Earnings Call Transcript
NovoCure Limited (NASDAQ:NVCR) Q1 2024 Earnings Call Transcript May 2, 2024 NovoCure Limited beats earnings expectations. Reported EPS is $-0.36134, expectations were $-0.43. NVCR isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for standing by. […]
- GuruFocus.com
NovoCure Ltd (NVCR) Q1 2024 Earnings: Revenue Surpasses Estimates, Narrower Net Loss Reported
Comprehensive Analysis of NovoCure's First Quarter Financial Performance
- Zacks
NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of 16.28% and 5.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
© 2024 Yahoo. All rights reserved.